(Q38293416)

1 September 2017

title

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor (English)

1 reference

1 September 2017

1 reference

M Y Chan

1

1 reference

1 September 2017

C P Rusconi

2

1 reference

1 September 2017

J H Alexander

3

1 reference

1 September 2017

R M Tonkens

4

1 reference

1 September 2017

R A Harrington

5

1 reference

1 September 2017

R C Becker

6

1 reference

1 September 2017

publication date

18 February 2008

1 reference

Journal of Thrombosis and Haemostasis

1 September 2017

published in

1 reference

1 September 2017

volume

6

1 reference

1 September 2017

issue

5

1 reference

1 September 2017

page(s)

789-796

1 reference

Combined antiplatelet and anticoagulant therapy: clinical benefits and risks

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

Factor IXa inhibitors as novel anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

The intrinsic pathway of coagulation: a target for treating thromboembolic disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

Coagulation disorders of cardiopulmonary bypass: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

RNA aptamers as reversible antagonists of coagulation factor IXa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.02932.X

10.1111/J.1538-7836.2008.02932.X

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference